PT  - JOURNAL ARTICLE
AU  - Alexandra Tauzin
AU  - Mehdi Benlarbi
AU  - Halima Medjahed
AU  - Yves Grégoire
AU  - Josée Perreault
AU  - Gabrielle Gendron-Lepage
AU  - Laurie Gokool
AU  - Chantal Morisseau
AU  - Pascale Arlotto
AU  - Cécile Tremblay
AU  - Daniel E. Kaufmann
AU  - Valérie-Martel-Laferrière
AU  - Inès Levade
AU  - Marceline Côté
AU  - Gaston de Serres
AU  - Renée Bazin
AU  - Andrés Finzi
TI  - Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination
AID  - 10.1101/2022.12.20.22283723
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.20.22283723
4099  - http://medrxiv.org/content/early/2022/12/20/2022.12.20.22283723.short
4100  - http://medrxiv.org/content/early/2022/12/20/2022.12.20.22283723.full
AB  - The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono-or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected recognize and neutralize better the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by le Ministere de l Economie et de l Innovation du Quebec, Programme de soutien aux organismes de recherche et d innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 to A.F. The PlasCov biobank was supported by funding from the COVID-19 Immunity Task Force (CITF) which is supported by the Public Health Agency of Canada (PHAC). Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Quebec Sante (FRQS) to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. C.T. is the Pfizer/Universite de Montreal Chair on HIV translational research. V.M.-L is supported by a FRQS Junior 2 salary award. A.T. was supported by MITACS Acceleration postdoctoral fellowship. M.B. was the recipient of a CIHR master scholarship award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare no competing interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All work was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. Blood samples were obtained from donors who consented to participate in this research project at Centre Hospitalier de l Universite de Montreal (CHUM) and Hema-Quebec. The study was approved by the Institutional Review Boards (no. 19.381 at CHUM and Hema-Quebec (2022-016)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors